Phase 2RecruitingPriority 3 · Moderate priorityNCT05976997
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
Plain-language summary
This Phase 2 trial is evaluating Duvelisib and Chidamide as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Duvelisib, Chidamide (DRUG): Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;
- Drugs / treatments
- Duvelisib, Chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details